Swipe om te navigeren naar een ander artikel
Chronic Hepatitis C (CHC) Virus infection is a serious health issue in the US. Standard treatment involves peginterferon alpha and ribavirin, often associated with adverse side effects including flu-like symptoms. These adverse effects are common reasons for the discontinuation of treatment and therefore represent a major obstacle in the effective treatment of CHC.
The Hepatitis Physical Symptom Severity Diary, a newly developed patient-reported outcome measure for assessing physical symptoms in CHC patients, was recently developed. It contains four questions addressing flu-like symptoms [the Flu-Like Symptom Index (FLSI)]. Measurement properties of the FLSI in CHC patients were assessed using data from two randomized clinical trials.
Exploratory factor analysis using data from baseline and the last visit while on treatment supported a single-factor solution for the FLSI. Internal reliability and test–retest reliability are acceptable (Cronbach’s alpha range 0.73–0.81; intraclass correlation coefficient range 0.85–0.97), and correspondence to several similar constructs was acceptable. The FLSI score was higher among those with investigator-reported flu-like symptoms (mean = 4.1) versus those without (1.4), although not statistically significant (p = 0.12). Responsiveness of the FLSI was moderate, as measured by standardized effect sizes and response means, and the minimum important difference (MID) was estimated at 2.5–3.0 points.
While additional research should be conducted to evaluate validity with more closely related constructs and to utilize anchor-based methods for estimating the MID, data suggest that the FLSI has acceptable measurement properties and can be an effective tool in assessing flu-like symptoms in CHC patients.
CDC. (2012). Hepatitis C information for health professionals. http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed January 24, 2012.
WHO. (2012). Hepatitis C key facts. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed March 26, 2012.
Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual data report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, p. 62.
Ghany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2011). An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology, 54(4), 1433–1444. PubMedCentralPubMedCrossRef
Nogueira, J. B., Santana Sena, L. C., de Souza Siqueira Quintans, J., Guedes da Silva Almeida, J. R., Vianey Callado França, A., & Quintans Júnior, L. J. (2011). Side effects of the therapy with peginterferon and ribavirin in chronic hepatitis C: A small audit . Journal of Pharmacy Practitioners, 25(1), 85–88.
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. The Lancet, 58, 958–965. CrossRef
Hauber, A. B., Mohamed, A. F., Beam, C., Medjedovic, J., & Mauskopf, J. (2011). Patient preferences and assessment of likely adherence to hepatitis C virus treatment. Journal of Viral Hepatitis, 18, 619–627. CrossRef
Yood, M. U., Sapra, S., Oliveria, S. A., Casso, D., Cziraky, M., Fu, A. C., L’Italien, G. J. (2011). Virologic response among hepatitis C patients treated in clinical practice. In Presented at the American Association for the Study of Liver Diseases Annual Meeting, November 4–8, 2011. San Francisco, CA.
Spiegel, B. M., Younossi, Z. M., Hays, R. D., Revicki, D., Robbins, S., & Kanwal, F. (2005). Impact of hepatitis C on health-related quality of life: A systematic review and quantitative assessment. Hepatology, 41(4), 790–800.
Taylor-Young, P., & Hildebrandt, E. (2009). The multidimensional burden of hepatitis C and its treatment: A case study. Gastroenterology Nursing, 32(3), 180–187.
Frankel, L., McGraw, S., Wongcharatrawee, S., & Garcia-Tsao, G. (2006). Patients’ experiences related to anti-viral treatment for hepatitis C. Patient Education and Counseling, 62(1), 148–155. CrossRef
Zickmund, S. L., Bryce, C. L., Blasiole, J. A., Shinkunas, L., LaBrecue, D. R., & Arnold, R. M. (2006). Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. European Journal of Gastroenterology and Hepatology, 18(4), 381–388. PubMedCrossRef
Kleinman, L., Mannix, S., Yuan, Y., Kummer, S., L’Italien, G., & Revicki, D. (2012). Review of patient-reported outcome measures in chronic hepatitis C. Health and Quality of Life Outcomes, 10, 92.
Mathias, S. D., Crosby, R. D., Bayliss, M. S., Hillson, J., Horga, M., Litallien, G., & Sapra, S. (2011). Chronic Hepatitis-C-related flu-like symptoms: Development of a patient-reported outcome measure and results from pilot efficacy studies. Value in Health, 14(A233–A510), A396.
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Manual for the beck depression inventory-II. San Antonio, TX: Psychological Corp.
Chapman, J., Oser, M., Hockemeyer, J., Weitlauf, J., Jones, S., & Cheung, R. (2011). Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: A prospective evaluation. American Journal of Gastroenterology, 106(12), 2123–2132. doi: 10.1038/ajg.2011.252. PubMedCrossRef
Arora, S., O’Brien, C., Zeuzem, S., Shiffman, M. L., Diago, M., Tran, A., et al. (2006). Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: Impact on health-related quality of life. Journal of Gastroenterology and Hepatology, 21(2), 406–412. PubMedCrossRef
Nunnally, J., & Bernstein, I. (1994). Psychometric theory. NY: McGraw Hill.
Kerlinger, F. N. (1973). Foundations of behavioral research. NY: Holt, Reinehart and Winston.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Erlbaum.
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592. PubMed
- Measurement properties of the Flu-Like Symptom Index from the Hepatitis Physical Symptom Severity Diary
Ross D. Crosby
Martha S. Bayliss
- Springer International Publishing